What is potent acid inhibition, and how can it be achieved?
- PMID: 16335854
- DOI: 10.2165/00003495-200565001-00004
What is potent acid inhibition, and how can it be achieved?
Abstract
The clinical response to antisecretory treatment correlates directly with the degree of inhibition of acid secretion achieved. Acid inhibition able to maintain the intragastric pH at a value greater than 4 for at least 16 h/day seems to heal even the most refractory acid-related diseases. It has also been shown that the degree of inhibition of acid secretion in response to antisecretory treatment depends on the genetic characteristics of the patient and on the presence of Helicobacter pylori infection. A possible definition of potent (or profound) acid inhibition is, therefore, the achievement of the aforementioned level of control of acid secretion regardless of patient characteristics or of the presence of H. pylori infection. Antisecretory drugs differ in their ability to reach potent acid inhibition. As far as the comparative efficacy of different drugs for inhibiting acid secretion is concerned, proton pump inhibitors are more efficient in inhibiting gastric acid secretion than histamine (H2) receptor antagonists. Among the different proton pump inhibitors, esomeprazole 40 mg/day exhibits greater antisecretory potency than the others at standard doses. Rabeprazole 20 mg/day and lansoprazole 30 mg/day exhibit a more rapid onset of action than omeprazole 20 mg/day or pantoprazole 40 mg/day.
Similar articles
-
[All proton pump inhibitors are equally efficacious in standard dosages].Lakartidningen. 2003 Jun 19;100(25):2212-6. Lakartidningen. 2003. PMID: 12872509 Review. Swedish.
-
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.Eur J Clin Pharmacol. 2004 Oct;60(8):531-9. doi: 10.1007/s00228-004-0804-6. Epub 2004 Sep 2. Eur J Clin Pharmacol. 2004. PMID: 15349707 Clinical Trial.
-
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.Am J Gastroenterol. 2003 Dec;98(12):2616-20. doi: 10.1111/j.1572-0241.2003.08783.x. Am J Gastroenterol. 2003. PMID: 14687806 Clinical Trial.
-
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.Aliment Pharmacol Ther. 2003 Jun 15;17(12):1507-14. doi: 10.1046/j.1365-2036.2003.01496.x. Aliment Pharmacol Ther. 2003. PMID: 12823153 Clinical Trial.
-
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].Presse Med. 2004 Jun 19;33(11):746-54. doi: 10.1016/s0755-4982(04)98731-3. Presse Med. 2004. PMID: 15257232 Review. French.
Cited by
-
Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.World J Gastroenterol. 2014 Apr 21;20(15):4362-9. doi: 10.3748/wjg.v20.i15.4362. World J Gastroenterol. 2014. PMID: 24764674 Free PMC article. Clinical Trial.
-
Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.J Gastroenterol. 2020 Nov;55(11):1054-1061. doi: 10.1007/s00535-020-01723-6. Epub 2020 Sep 15. J Gastroenterol. 2020. PMID: 32930864
-
Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes.J Clin Biochem Nutr. 2016 Sep;59(2):149-153. doi: 10.3164/jcbn.16-18. Epub 2016 Jul 16. J Clin Biochem Nutr. 2016. PMID: 27698544 Free PMC article.
-
Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.Clin Exp Med. 2018 Nov;18(4):569-576. doi: 10.1007/s10238-018-0510-9. Epub 2018 Jun 6. Clin Exp Med. 2018. PMID: 29876770 Clinical Trial.
-
The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.Prz Gastroenterol. 2017;12(4):244-249. doi: 10.5114/pg.2017.72097. Epub 2017 Dec 14. Prz Gastroenterol. 2017. PMID: 29358992 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials